The BRD4‐targeting drugs JQ1 (Figure S11) and dBET6 (Figure S12) were also able to counteract the cytokine‐induced PD‐L1 expression in MPN cell lines and MPN NSC. Here, BRD4 is linked to myeloproliferative disorder.